Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies
A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Subjects Who Have Failed Prior Treatment With Sofosbuvir-based Therapies
Sponsor: Gilead Sciences
Terminated
Due to lack of feasibility of enrolling participants, the study was terminated early.
Listed as NCT02600351, this PHASE3 trial focuses on Hepatitis C Virus Infection and remains terminated or withdrawn. Sponsored by Gilead Sciences, it has been updated 14 times since 2015, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 9 earlier versions
-
Dec 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Oct 2018 — Dec 2018 [monthly]
Terminated PHASE3
-
Jul 2018 — Oct 2018 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
May 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Aug 2017 — May 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .